Since primary myelofibrosis (PMF) originates at the level of the pluripotent hematopoietic stem cell (HSC), we examined the effects of various therapeutic agents on the in vitro and in vivo behavior of PMF CD34 + cells. Treatment of PMF CD34 + cells with chromatin modifying agents (CMA) but not hydroxyurea, JAK2 inhibitors or low doses of IFN-α led to the generation of greater numbers of CD34 + CXCR4 + cells, which were capable of migrating in response to CXCL12 and resulted in a reduction in the proportion of HPCs that were JAK2V617F + . Furthermore, sequential treatment of PMF CD34 + cells but not normal CD34 + cells with decitabine [5-aza-2'-deoxycytidine (5azaD)], followed by suberoylanilide hydroxamic acid (SAHA) (5azaD/SAHA), or trichostatin A (5azaD/TSA) resulted in a higher degree of apoptosis. Two to six months after the transplantation of CMA treated JAK2V617F + PMF CD34 + cells into NOD/SCID/IL2Rγ null mice, the percentage of JAK2V617F/JAK2 total in hCD45 + marrow cells was dramatically reduced. These findings suggest that both PMF HPCs, short-term and long-term SCID repopulating cells (SRC) are JAK2V617F + and that JAK2V617F + HPC and SRC can be eliminated by sequential treatment with CMAs. Sequential treatment with CMAs, therefore, represents a possible effective means of treating PMF at the level of the malignant SRC.
Introduction
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) , which is thought to originate at the level of a pluripotent hematopoietic stem cell (HSC). [1] [2] [3] [4] [5] A gain of function mutation in the JH2 domain of the Janus kinase 2 (JAK2V617F) has been identified in the MPNs, which is present in the granulocytes of approximately 95% of patients with polycythemia vera and 50% of patients with either PMF or essential thrombocythemia. In about 10% of patients with JAK2V617F negative PMF, an additional somatic mutation of the thrombopoietin receptor gene MPL has also been identified. 6 Furthermore, malignant clones harboring additional genetic abnormalities including the TET oncogene family member 2 (TET2), the additional sex combs like gene and the gene for isocitrate dehydrogenase 1 as well as characteristic cytogenetic abnormalities have been observed in PMF indicating that multiple genetic events are likely responsible for the origins of this MPN. 7 Epigenetic modifications leading to the dysregulation of critical genes that contribute to cell proliferation, differentiation, cell death and trafficking have also been thought to play a role in the origins of PMF. [8] [9] Mutations in TET2, for instance, might contribute to the origins of PMF by altering chromatin structure. TET1 affects the conversion of 5-methylcytosine to 5-hydroxymethylcytosine and therefore influences epigenetic For personal use only. on January 22, 2018. by guest www.bloodjournal.org From regulation of transcription. 10 Previously we had reported that the constitutive mobilization of CD34 + cells in PMF could be accounted by in part by the reduced expression of the chemokine receptor CXCR4 by PMF CD34 + cells which has been attributed to hypermethylation of its promoter. 11 In addition, we have reported that the sequential treatment of PMF CD34 + cells with a DNA methyltransferase (DNMT) inhibitor (DNMTI), 5-aza-2'-deoxycytidine (5azaD), followed by an histone deacetylase (HDAC) inhibitor (HDACI), trichostatin A (TSA), resulted in an upregulation of CXCR4 expression by PMF CD34 + cells leading to correction of the abnormal cellular trafficking characteristic of PMF as well as a reduction of the burden of malignant HPC. 12, 13 These preclinical studies illustrate the profound effects of chromatin modifying agents (CMA) on PMF HPC and led us to further evaluate these strategies this time using drugs that are currently approved for the treatment of other hematological malignancies and to determine if they affect malignant stem cells.
We hypothesize that curative drug therapies for PMF would ideally eliminate or at least reduce the burden of PMF HSCs/HPCs, allowing their normal counterparts to predominant. Currently, the standard surrogate assay for human HSCs assesses the ability of a putative HSC population to establish hematopoiesis in immunodeficient mice. In this report, we provide evidence that sequential treatment with 5azaD followed For personal use only. on January 22, 2018. by guest www.bloodjournal.org From by the HDACI, suberoylanilide hydroxamic acid (SAHA), not only affects PMF HPC but also stem cells. Sequential treatment with CMA, therefore, represents a promising therapeutic strategy for the treatment of PMF patients.
Materials and Methods

Description of patients and cell isolation procedures
Peripheral blood (PB) was collected from 32 patients who fulfilled the WHO diagnostic criteria for PMF. 14 Granulocytes were isolated by previously described techniques. 15 For personal use only. on January 22, 2018. by guest www.bloodjournal.org From JAK2V617F and MplW515L mutational analyses JAK2V617F and MplW515L were detected by analyzing the PB granulocytes of patients with PMF by using a real-time quantitative PCR assay using an allelic discrimination method as described previously. 16 The JAK2V617F status and allele burden of each patient studied is provided in Supplemental Table 1 . Among the 32 PMF subjects, 18 patients were JAK2V617F positive while none possessed MplW515L. The JAK2V617F negative patients were further analyzed for marker chromosomal abnormalities using fluorescence in situ hybridization (FISH). 17 Patient 32 was characterized by a marker chromosomal abnormality [Del (13)(q13)] that could be detected by FISH.
Treatment of CD34 + cells with various therapeutic agents
PMF CD34 + cells (1×10 5 /ml) were cultured in Iscove's modified Dulbecco's medium (IMDM; Lonza, Walkersville, MD, USA) containing 30% fetal bovine serum (FBS;
HyClone Laboratories, Logan, UT) supplemented with 100 ng/ml stem cell factor (SCF), 100 ng/ml FLT-3 ligand (FL), 100 ng/ml thrombopoietin (TPO), and 50 ng/ml interleukin-3 (IL-3) (Amgen, Thousand Oaks, CA, USA) and incubated in a humidified incubator maintained at 37°C with 5% CO 2 . After an initial 16 hours of incubation, cells were either exposed to 5azaD (1uM, Pharmachemie B.V., GA Haarlem, Nederland) for interferon-α 2a (Peg-IFN-α 2a, 125U, Roche, Nutley, NJ) alone for 3 days. In addition, CD34 + cells were exposed to 5azaD at a concentration of 1uM for 48 hours, and then washed and distributed to new culture plates containing SCF, FL, and TPO with either SAHA, for an additional 6-day culture period, or TSA (16.5nM, Sigma) for a 7-day culture period. 12, 13 In addition, cultures containing cytokines alone were performed in parallel. In some experiments, the cultured PMF CD34 + cells were re-isolated as described above after a period of culture and assayed for their ability to migrate in vitro in response to CXCL12 or to form hematopoietic colonies in semisolid media.
In order to determine if CMA were able to affect normal hematopoietic stem/progenitor cells, CB CD34 + cells (1×10 5 /ml) were also cultured and treated with CMA in an identical fashion.
Flow cytometric analysis of CD34 + cells
Primary CD34 + cells and CD34 + cells isolated after incubation were labeled with anti-human CD34 monoclonal antibody (mAb) conjugated to allophycocyanin (APC) and CXCR4 mAb (clone# 12G5) conjugated to phycoerythrin (PE). All mAb were For personal use only. on January 22, 2018. by guest www.bloodjournal.org From purchased from Becton Dickinson Pharmingen. Each analysis was paired with a corresponding matched isotype control. Immediately before flow cytometric analysis, 1 µg/ml of propidium iodide (Sigma) was added in order to exclude nonviable cells. Cells were analyzed flow cytometrically and at least 10,000 viable cells were acquired from each sample (Cell-Quest software, Becton Dickinson).
The percentage of CD34 + cells undergoing apoptosis was determined using the Annexin V-FITC apoptosis detection kit (BD Pharmingen). CD34 + Annexin V + PIcells were regarded as cells undergoing apoptosis.
Migration assay
The migratory behavior of primary PMF CD34 + cells before and following culture was determined as previously described using 6.5-mm-diameter, 5-µm-pore transwell plates (Corning, NY). 15, 18 The percentage of cells migrating was calculated by determining the ratio of the number of cells recovered from the lower compartment to the total number of cells loaded in the upper compartment. Migrating cells were also assayed in semisolid media for their ability to form hematopoietic colonies and those colonies were plucked and their JAK2 status determined. 19
Hematopoietic progenitor cell assays 1 0 Primary CD34 + cells or CD34 + cells reisolated following culture with cytokines or cytokines plus various agents were assayed in semisolid media as described previously. 19 Briefly, 5 × 10 2 cells were plated in duplicate culture dishes containing 1 ml IMDM with 1.1% methylcellulose, 30% FBS, 5 × 10 -5 mol/L 2-mercaptoethanol (Stem Cell Technologies), to which SCF, thrombopoietin, IL-3, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), each at 100 ng/ml, and 5 units/ml of erythropoietin (Amgen) were added. Colonies were enumerated after 12-14 days of incubation. Individual colonies were plucked and analyzed for the JAK2V617F using a nested allele-specific PCR as previously described 19 and the percentage of JAK2V617F-positive colonies formed was determined.
NOD/SCID Marrow Repopulating Cell Assay
NOD/SCID/IL2R null mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). All experiments were approved by the Animal Care Committee of the MSSM. PMF CD34 + cells from 7 patients with a granulocyte JAK2V617F allele burden ranging from 35% to 86% were treated with 5azaD/SAHA or 5azaD/TSA and their cellular phenotype analyzed, their ability to form hematopoietic colonies in vitro and the JAK2V617F status of individual colonies determined. Also, primary PMF CD34 + cells or the total number of cells generated after culture from the identical number of PMF 
Statistical analysis
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The results are reported as the mean ± SD of data obtained from 4-6 individual experiments. Statistical significance was determined using Student's t tests or paired-sample t tests. All P values were two-sided.
Results
5azaD/SAHA treatment increases the numbers of PMF CD34 + CXCR4 + cells
Bogani C et al have previously reported that a short-term in vitro treatment with 5-azaD reduced CXCR4 promoter methylation, increased membrane expression of CXCR4 and resulted in improved migration of CD34 + cells in response to CXCL12 in vitro. 11 In addition we have shown that sequential treatment of PMF CD34 + cells with 5azaD/TSA, resulted in an upregulation of CXCR4 expression by PMF CD34 + cells and correction of the abnormal cellular trafficking characteristic of PMF as well as a reduction of the burden of malignant HPC. 12, 13 We, therefore, explored if similar activity could be achieved with an HDACI which is currently approved for clinical use in order to develop a strategy for treating patients with PMF. SAHA is an HDACI currently approved to treat patients with cutaneous T-cell lymphoma (CTCL). 20 We evaluated the effects of 5azaD or SAHA alone or the sequential treatment with these two CMA on PMF CD34 + cells. 1 3 CD34 + cells were first treated with cytokines alone or cytokines plus 5azaD for 2 days and were phenotypically characterized. As shown in Fig. 1A and 1B, a similar reduction in the total number of cells and CD34 + cells were observed in the cultures of incubated with cytokines alone or cytokines plus 5azaD alone. The percentage of CD34 + cells which expressed CXCR4 was, however, significantly greater (8.2±1.5%) following 5azaD treatment than that achieved with cells exposed to cytokines alone (3.6±0.6%; P<.05) or primary PMF CD34 + cells (1.6±0.3%; P<.01) (Fig. 1C ). The number of CD34 + cells which expressed CXCR4 in cultures containing cytokines plus 5azaD (4.3±1.8×10 3 ) was 2-fold greater than that detected in cultures exposed to cytokines alone (2.1±0.9×10 3 ; P=.08; Fig. 1D ).
We next examined the effect of SAHA treatment alone on PMF CD34 + cells.
Incubation of CD34 + cells with cytokines alone resulted in a 5.8-to 10.2-fold increase, while treatment with the same cytokines and SAHA resulted in a 2-to 7-fold increase in the total number of cells as compared to the number of input cells (Fig 1 A; P=.11 ). The number of CD34 + cells in cultures containing cytokines alone (2.8±1.2×10 5 ) was statistically similar to the number in cultures exposed to cytokines plus SAHA (1.4±0.9×10 5 ; P=.37; Fig. 1B ), and the absolute number of CD34 + cells expressing CXCR4 in cultures containing cytokines plus SAHA (3.4±2.8×10 3 
) was only half that
For personal use only. on January 22, 2018. by guest www.bloodjournal.org From observed in the cells exposed to cytokines alone ( Fig. 1D ). These findings suggest that treatment with SAHA alone does not enhance the expression of CXCR4 by PMF CD34 + cells.
We next investigated the effects of the sequential treatment with 5azaD and SAHA on PMF CD34 + cells. PMF CD34 + cells cultured ( Fig. 1A) in the presence of cytokines plus 5azaD/SAHA generated more total cells (10.0±1.9×10 5 ) than the number of primary cells used to initiate the cultures (1.1±0.01×10 5 ) (P<.001) but fewer cells than that observed in cultures containing cytokines alone (18.5±2.4×10 5 , P<.001). The absolute number of CD34 + cells in cultures exposed to cytokines alone (1.5±0.5×10 5 ) was similar to that documented in cultures exposed to cytokines plus 5azaD/SAHA (0.9±0.2×10 5 ) (Fig.1B) . The percentage of CD34 + cells which expressed CXCR4 was, however, significantly greater (22.3±1.9%) following 5azaD/SAHA treatment than that achieved following exposure to cytokines alone (6.2±1.1%; P<.001), primary PMF CD34 + cells (1.6±0.3%; P<.001) or cells exposed to 5azaD alone (P<.05) or SAHA alone (P<.01) (Fig. 1C ). The number of CD34 + cells which expressed CXCR4 in cultures containing cytokines plus 5azaD/SAHA was greater than that present in primary CD34 + cells (P<.001) or cells exposed to cytokines alone (P<.001), 5azaD alone (P<.05) or SAHA alone (P<.05) ( Fig. 1D ). This effect of 5azaD/SAHA on 1 5
CXCR4 expression was observed irrespective of the JAK2 mutational status of the patients studied (data not shown).
5azaD/SAHA treatment increases the migratory capacity of PMF CD34 + cells in response to CXCL12
The reisolated 5azaD/SAHA treated PMF CD34 + cells had a greater capacity to migrate toward CXCL12 (19.2±3.96%) as compared with CD34 + cells exposed to cytokines alone (6.2±1.3%, P<.05) or primary CD34 + cells (4.4±1.6%, P<.05) ( Fig. 2A ).
The JAK2 mutational status of HPCs (CFU-GM, BFU-E and CFU-Mix) from 4 patients (JAK2V617F granulocyte allele burden ranging from 37% to 77%) that migrated in response to CXCL12 was then analyzed. Both the percentage and total number of JAK2 wild type colonies assayed from CD34 + cells treated with cytokines plus 5azaD/SAHA that had migrated was significantly greater (40.9±5.8%; 347±74.0) than JAK2 wild type colonies assayed from CD34 + cells exposed to cytokines alone that had migrated (11.3±5.3%, P<.001; 45±11.4, P<.05) or primary PMF CD34 + cells that had migrated (7.2±3.9%, P<.01; 9.8±3.8, P<.05) ( Fig. 2B and 2C ).
5azaD/SAHA treatment reduces the percentage of malignant PMF HPCs
We further investigate the effect of SAHA alone or 5azaD/SAHA on PMF HPC. As shown in Fig. 3A , a similar number of HPC were assayed from PMF CD34 + cells For personal use only. on January 22, 2018. by guest www.bloodjournal.org From treated with SAHA as that assayed from CD34 + cells exposed to cytokines alone or primary PMF CD34 + cells. Individual colonies from two JAK2V617F positive PMF patients (JAK2V617F allele burden of granulocytes was 60% and 77%) were plucked and analyzed for the JAK2V617F using a nested allele-specific PCR. As shown in Table   1 , the treatment of PMF CD34 + cells with SAHA alone did not substantially reduce the percentage of JAK2V617F positive colonies or JAK2V617F homozygous colonies.
By contrast, 5azaD/SAHA treatment resulted in a marked reduction of all classes of assayable progenitor cells (CFU-GM, BFU-E, CFU-Mix), as compared with PMF CD34 + cells exposed to cytokines alone (P<.05) or primary PMF CD34 + cells (P=.08) ( Fig. 3B and 3C ). The inhibitory effect of 5azaD/SAHA treatment on PMF HPCs was similar to that previously reported with 5azaD/TSA treatment. 12 We further analyzed the JAK2V617F status of HPCs assayed from PMF CD34 + cells treated with 5azaD/SAHA from 6 different patients (JAK2V617F granulocyte allelic burden of ranging from 35% to 80%). CD34 + cells were reisolated following treatment of cells from these same patients with either cytokines alone or cytokines plus 5azaD/SAHA. As shown in Table 2 , 5azaD/SAHA treatment resulted in not only a reduction in the proportion of JAK2V617F + HPCs (53.7±10.1%) as compared to cells exposed to cytokines alone (81.8±7.5%, P<.01) or primary PMF CD34 + cells 1 7 (82.5±8.3%, P<.01) but also a reduction in the proportion of JAK2V617F homozygous HPCs (13.4±6.5%) as compared to cells exposed to cytokines alone (33.4±9.7%, P<.05) or primary PMF CD34 + cells (55.3±15.1%, P=.09).
In addition, in a single case with JAK2V617F negative PMF but with a marker chromosomal abnormality [Del (13)(q13)] (Patient 32), the effect of 5azaD/SAHA treatment on the malignant clone was examined by performing FISH analysis of the cells within colonies. 53.8% of the colonies cloned from primary CD34 + cells from this patient were composed of cells where >90% contained the marker chromosomal abnormality as compared to 46.2% in cultures exposed to cytokines alone while only colonies containing cells lacking the chromosomal abnormality were observed in the culture exposed to cytokines plus 5azaD/SAHA. These data suggest that 5azaD/SAHA treatment can preferentially eliminate the malignant HPC of PMF patients with genetic defects other than JAK2V617F.
5azaD/SAHA treatment does not affect normal CD34 + cells
We next examined the effects of 5azaD/SAHA treatment on CB CD34 + cells. As shown in Fig 4A and 4B , the absolute number of CB CD34 + cells and assayable HPC in cultures exposed to cytokines alone was similar to that detected in cultures exposed to cytokines plus 5azaD/SAHA. The percentage of cells within the 5azaD/SAHA-treated For personal use only. on January 22, 2018. by guest www.bloodjournal.org From CB CD34 + cells which expressed CXCR4 was, however, 1.9 times greater than the cells exposed to cytokines alone (Fig. 4C ). In addition, treatment of CB CD34 + cells in vitro with cytokines plus 5azaD/SAHA resulted in a 1.8-fold increase in the absolute numbers of CD34 + CXCR4 + cells as compared to CD34 + cells exposed to cytokines alone ( Fig.   4D ). These findings suggest that 5azaD/SAHA treatment at the doses utilized is not toxic to normal CD34 + cells but does result in up-regulated CXCR4.
5azaD/SAHA treatment induces the apoptosis of PMF CD34 + cells
In order to explore additional mechanisms by which 5azaD/SAHA affects PMF CD34 + cells, we determined if sequential treatment with CMAs was associated with an increased degree of apoptosis. As shown in Fig. 5B , the percentage of CD34 + Annexin V + PIcells were significantly greater in PMF CD34 + cells treated with cytokines plus 5azaD/SAHA (13.2±3.5%) as compared to that observed with PMF CD34 + cells treated with cytokines alone (0.9±0.9%, P<.05). Remarkably treatment of CB CB34 + cells with the same doses of 5azaD/SAHA in the presence of cytokines was not associated with the same degree of apoptosis (0.4±0.4%), indicating that PMF CD34 + cells are more sensitive than CB CD34 + cells to the actions of these CMA.
Effects of JAK2 inhibitors, Peg-IFN-α 2a or hydroxyurea on PMF CD34 + cells
The current standard of care for PMF patients include hydroxyurea, and interferon-α Table 3) . Similarly treatment with none of these agents altered CXCR4 expression by CD34 + cells. A similar number of HPC were assayed from CD34 + cells treated with cytokines plus each of these agents individually as that assayed from primary CD34 + cells or CD34 + cells exposed to cytokines alone. None of these agents substantially reduce the percentage of JAK2V617F colonies or JAK2V617F homozygous colonies (Table 4 ). These findings suggest that unlike 5azaD/SAHA, none of these agents was capable of eliminating JAK2V617F HPC or For personal use only. on January 22, 2018. by guest www.bloodjournal.org From 0 upregulating CXCR4 expression by PMF CD34 + cells.
Effects of sequential treatment with chromatin modifying agents on PMF SCID repopulating cells (SRC)
Following transplantation, short-term SCID repopulating cells (SRC) are thought to contribute to hematopoiesis initially but their contribution to blood cell production persists for only a limited period of time, while long-term SRCs are thought to contribute to hematopoiesis after a delay but to be responsible for sustained blood cell production. 22 These classes of SRC can be distinguished by monitoring the kinetics of engraftment in immunodeficient mice. We therefore evaluated the effect of sequential treatment with CMAs on short-term SRCs assayed 2 months following transplantation and long-term SRCs, assayed 4 or 6 months following transplantation. CD34 + cells from 7 patients (JAK2V617F allele burden of granulocytes ranged from 35% to 86%) were transplanted and the JAK2V617F allele burden of hCD45 + cells was determined in the marrow of NOD/SCID/IL2Rγ null mice. Two months following transplantation, 4.4% of the marrow cells were hCD45 + cells in mice receiving primary CD34 + cells from Patient 4 as compared to 0.2% in mice receiving cells treated with cytokines alone or cytokines and 5azaD/TSA. The donor cells receiving primary PMF CD34 + cells were composed of myeloid cells belonging to multiple hematopoietic lineages (CD33 + cells, 4.3%;
For personal use only. on January 22, 2018. by guest www.bloodjournal.org From 1 glycophorin A + cells, 0.8%; CD41a + cells, 0.1% and CD34 + cells, 0.2%) but not CD19 + or CD3 + cells (Patient 4, Fig. 6 ). The percentage of JAK2V617F/JAK2 total in hCD45 + cells from BM of the two mice transplanted with primary CD34 + cells from this patient was 71.5% and 34.7% in mice transplanted with cells treated with cytokines alone and 6.8% in mice transplanted with cells treated with 5azaD/TSA ( Similarly, six months following transplantation, human marrow cell chimerism was also documented (Table 5, 
Discussion
In the present report, we showed that the in vitro treatment with sequential 5azaD/SAHA or 5azaD/TSA but not 5azaD or SAHA alone had a profound effect on PMF CD34 + cells, resulting in a dramatic reduction in the number of JAK2V617F + HPCs. These effects were not observed following the treatment with other agents including JAK2 inhibitors, hydroxyurea or peg-IFN-α 2a. We have chosen to use SAHA for these studies since clinical trials and animal models have shown that SAHA can induce growth arrest, and death of cancer cells in vitro and in vivo, at concentrations that have little or no toxicity for normal cells. [23] [24] [25] [26] [27] We have demonstrated that both For personal use only. on January 22, 2018. by guest www.bloodjournal.org From Sequential treatment with 5azaD/SAHA at concentrations that resulted in the elimination of JAK2V617F + HPC and SRC was associated with increased apoptosis of PMF CD34 + cells but not normal CD34 + cells. Our laboratory has previously reported that the sequential treatment of normal HSCs with 5azaD and TSA results in their ability to undergo symmetrical cell division with retention of their marrow-repopulating potential. [29] [30] [31] This behavior is in contrast to stem cells exposed in vitro to cytokines alone which undergo progressive loss of their proliferative and self-renewal capacity.
Sequential treatment of normal stem cells with 5azaD/TSA results in the up-regulation of expression of number of genes previously implicated in HSCs self-renewal. 31 The effects of CMAs on MPN CD34 + cells could, therefore, be due not only to their ability to inducing apoptosis and terminal differentiation of malignant stem cells, but also their ability to promote preferential expansion of residual pool of JAK2 wild type stem cells.
Such wild type PMF stem cells are not necessary normal since they could contain additional genetic abnormalities (TET2, the additional sex combs like gene and the gene for isocitrate dehydrogenase 1, etc).
We also showed that the sequential treatment of PMF CD34 + cells with 5azaD/SAHA resulted in the restoration of their capacity to migrate toward CXCL12 which was associated with the upregulation of CXCR4 expression. Moreover, *Indicates the percentage of JAK2V617F allele obtained from granulocytes by real-time quantitative kinetic PCR assay using allelic discrimination method. † Each value represents the percentage of colonies (CFU-GM+BFU-E+CFU-Mix) exhibiting the JAK2V617F mutation or homozygous JAK2V617F allele. The numbers in parentheses denote the actual number of JAK2V617F positive or homozygous colonies/the total numbers of colonies (CFU-GM+BFU-E+CFU-Mix) analyzed.
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